Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
PATH, 4555 Massachusetts Ave NW, Washington, DC, USA.
Vaccine. 2019 Aug 7;37(34):4768-4774. doi: 10.1016/j.vaccine.2019.02.070.
PATH hosted the second Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Mexico City in June 2018, again providing experts from around the world an opportunity to participate in a highly collaborative forum to discuss progress in the development of new enteric vaccines. Through a combination of plenary sessions and posters, keynote presentations, and workshops, the 2018 VASE Conference aimed to accelerate communication and progress among those working to achieve the goal of licensed vaccines against these two bacterial pathogens. Many presentations recognized the importance of diarrheal disease and long-term sequelae caused by infections with Shigella and enterotoxigenic E. coli (ETEC). Other presentations explored new strategies for vaccine development, including the search for novel, possibly conserved, antigens for more effective vaccines. Much progress is being made as some vaccine candidates are now moving through clinical trials. Research presented in oral and poster presentations at the VASE Conference covered a range of topics, including: the global burden of disease, epidemiology, and health economics; host parameters and genomics that predict responses to infection and disease; preclinical evaluations of vaccine antigens and models of enteric diseases; and vaccine candidates in clinical trials and human challenge studies. This article reviews key points and highlighted research presented in each of the plenary conference sessions and poster presentations at the 2018 VASE Conference.
PATH 于 2018 年 6 月在墨西哥城主办了第二届志贺氏菌和肠产毒性大肠杆菌疫苗（VASE）会议，再次为来自世界各地的专家提供了一个参与高度协作论坛的机会，讨论开发新型肠内疫苗的进展。通过全体会议和海报、主题演讲和研讨会的结合，2018 年 VASE 会议旨在加速致力于实现针对这两种细菌病原体的许可疫苗这一目标的人员之间的沟通和进展。许多演讲都认识到腹泻病以及由志贺氏菌和肠产毒性大肠杆菌（ETEC）感染引起的长期后遗症的重要性。其他演讲探讨了疫苗开发的新策略，包括寻找新型、可能保守的抗原，以开发更有效的疫苗。随着一些候选疫苗现在进入临床试验，已经取得了许多进展。在 VASE 会议上的口头和海报演讲中介绍的研究涵盖了一系列主题，包括：疾病的全球负担、流行病学和健康经济学；预测对感染和疾病反应的宿主参数和基因组学；疫苗抗原的临床前评估和肠道疾病模型；以及临床试验和人体挑战研究中的候选疫苗。本文回顾了 2018 年 VASE 会议全体会议和海报演讲中介绍的每个重点和突出研究。
